Grace Therapeutics, Inc. GRCE · Stock Open Grace Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Grace Therapeutics, Inc. Analysis (GRCE)
Is Grace Therapeutics, Inc. a good investment? Grace Therapeutics, Inc. (GRCE) is currently trading at 2.02 USD. Market analysts have a consensus price target of 5.85 USD. This suggests a potential upside from current levels.
Earnings Schedule: Grace Therapeutics, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.45.
Investor FAQ
Does Grace Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Grace Therapeutics, Inc.?
Grace Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.18.
Company Profile
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 15, 2015 | 1:10 |
| Aug. 31, 2021 | 1:8 |
| July 10, 2023 | 1:6 |
Community Discussion